Atara Biotherapeutics announced Jan. 10 that it was cleared to enroll patients in a phase one clinical study to evaluate a T-cell immunotherapy treatment for multiple sclerosis. The company, which has its research and development headquarters in Westlake Village, got U.S. Food and Drug Administration approval for its investigational new drug application. The treatment uses…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
